Adam Shardlow and colleagues investigate whether using cystatin C in addition to serum creatinine can improve diagnosis and risk prediction for progression of CKD among patients in primary care, and estimate the costs of additional testing and monitoring. The gene discussed is CST3; the disease is chronic kidney disease.